FREQUENCY OF HORMONE RECEPTORS AND HER-2/NEU RECEPTOR POSITIVITY IN DIFFERENT HISTOLOGY IN BREAST CANCER PATIENTS

Authors

  • Ramchandani Ravi Jinnah postgraduate medical centre Karachi.
  • Ghulam Haider Jinnah postgraduate medical centre Karachi.
  • Khalil Ahmed Jinnah postgraduate medical centre Karachi.
  • Saima Zahoor Jinnah postgraduate medical centre Karachi.
  • Abdus Sami Jinnah postgraduate medical centre Karachi.
  • Ramchandani Lata Civil Hospital Tandollahyar , Sindh

Abstract

Background: This study was conducted to see the frequency of hormone receptors and Her-2/Neu positivity in different histology in breast cancer patients. Methods: It was a cross-sectional study conducted at the Department of Medical Oncology, Jinnah Postgraduate Medical Centre from June 2018- March 2019. Total 373 patients of age 22–81 years of which 360 female and 13 males, with histopathological proven diagnosis of breast cancer were included in the study using non-probability consecutive sampling technique. The immunohistochemistry (IHC) was performed on biopsy sample for the status of PR, ER and HER-2/Neu and the confirmation of Her-2/Neu was done by Fluorescent In situ Hybridization (FISH) technique if HER-2/Neu was equivocal by IHC testing. Information regarding demographics, family history, histology, grade, stage, metastatic site and other histopathological parameters were noted on predesigned proforma by the researcher. SPSS-23 was used to analyse data. Results: Total of 373 patients were included in the study. The mean patient age was 45.34±12.28 years. ER, PR, Her 2 Neu (IHC) & Her 2 Neu (FISH) were found positive in 206 (55.2%), 182 (48.8%), 121 (32.4%) & 23 (6.2%) patients, respectively. The histology with PR receptor & grade of tumour with ER & PR receptor showed statistical significance (p<0.05). Conclusion: ER, PR &HER-2/NEU expression in breast cancer vary among different population and it is very important to find out the frequency among different histopathological types as  it is of predictive and prognostic value. So, it is recommended to look for these markers and treat them accordingly.

Author Biographies

Ramchandani Ravi, Jinnah postgraduate medical centre Karachi.

Medical oncology,FCPS postgraduate trainee

Ghulam Haider, Jinnah postgraduate medical centre Karachi.

Associate Professor, Medical oncology,JPMC Karachi.

Khalil Ahmed, Jinnah postgraduate medical centre Karachi.

Consultant Oncology,Medical Oncology JPMC ,Karachi

Saima Zahoor, Jinnah postgraduate medical centre Karachi.

Consultant Oncology,Medical Oncology JPMC ,Karachi

Abdus Sami, Jinnah postgraduate medical centre Karachi.

Consultant Oncology,Medical Oncology JPMC ,Karachi

Ramchandani Lata, Civil Hospital Tandollahyar , Sindh

Medical officer Civil Hospital Tandollahyar , Sindh

References

Pietras RJ, Arboleda J, Reese DM, Wongvipat N, Pegram MD, Ramos L, et al. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 1995;10(12):2435–46.

Naeem M, Nasir A, Aman Z, Ahmad T, Samad A. Frequency of HER-2/neu receptor positivity and its association with other features of breast cancer. J Ayub Med Coll Abbottabad 2008;20(3):23–6.

Sughayer MA, Al-Khawaja MM, Massarweh S, Al-Masri M. Prevalence of hormone receptors and HER2/neu in breast cancer cases in Jordan. Pathol Oncol Res 2006;12(2):83–6.

Faheem M, Mahmood H, Khurram M, Qasim U, Irfan J. Estrogen receptor, progesterone receptor, and Her 2 Neu positivity and its association with tumour characteristics and menopausal status in a breast cancer cohort from northern Pakistan. Ecancermedicalscience 2012;6:283.

DeVita VT, Lawrence TS, Rosenberg SA, editors. DeVita, Hellman, and Rosenberg’s cancer: principles & practice of oncology. 9th ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins, 2011; p.2638.

Dutta V, Chopra GS, Sahai K, Nema SK. Hormone Receptors, Her-2/Neu and Chromosomal Aberrations in Breast Cancer. Med J Armed Forces India 2008;64(1):11–5.

Masood S. Assessment of prognostic factors in breast fine-needle aspirates. Am J Clin Pathol 2000;113(5 Suppl 1):S84–96.

Ambroise M, Ghosh M, Mallikarjuna VS, Kurian A. Immunohistochemical profile of breast cancer patients at a tertiary care hospital in South India. Asian Pac J Cancer Prev 2011;12(3):625–9.

Zubeda S, Kaipa PR, Shaik NA, Mohiuddin MK, Vaidya S, Pavani B, et al. Her-2/neu status: a neglected marker of prognostication and management of breast cancer patients in India. Asian Pac J Cancer Prev 2013;14(4):2231–5.

Stark A, Kleer CG, Martin I, Awuah B, Nsiah‐Asare A, Takyi V, et al. African ancestry and higher prevalence of triple‐negative breast cancer: findings from an international study. Cancer 2010;116(21):4926–32.

Lee JH PS, Park HS, Park BW. Clinicopathological features of infiltrating lobular carcinomas comparing with infiltrating ductal carcinomas: a case control study. World J Surg Oncol 2010;8(1):34–10.

Ohta T, Tusjimoto F, Nakajima Y, Fukuda M, Takag M. Ultrasonographic findings of invasive lobular carcinoma differentiation of invasive lobular carcinoma from invasive ductal carcinoma by ultrasonography. Breast Cancer 2005;12(4):8–10.

Radojicic J, Zaravinos A, Vrekoussis T, Kafousi M, Spandidos DA, Stathopoulos EN. MicroRNA expression analysis in triple-negative (ER, PR and Her2/neu) breast cancer. Cell Cycle 2011;10(3):507–17.

Van de Ven S, Smit VT, Dekker TJ, Nortier JW, Kroep JR. Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer. Cancer Treat Rev 2011;37(6):422–30.

Khabaz MN. Immunohistochemistry subtypes (ER/PR/HER) of breast cancer: where do we stand in the West of Saudi Arabia. Asian Pac J Cancer Prev 2014;15(19):8395–400.

Lund MJ BE, Hair BY, Ward KC, Andrews JH, Oprea-Ilies G, Bayakly AR, et al. Age/race differences in HER2 testing and in incidence rates for breast cancer triple subtypes: a population-based study and first report. Cancer 2010;116(11):2549–59.

Carey LA PC, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006;295(21):2492–502.

Porter PL, Lund MJ, Lin MG, Yuan X, Liff JM, Flagg EW, et al. Racial differences in the expression of cell cycle-regulatory proteins in breast carcinoma. Cancer 2004;100(12):2533–42.

Huang HJ, Neven P, Drijkoningen M, Paridaens R, Wildiers H, Van Limbergen E, et al. Hormone receptors do not predict the HER2/neu status in all age groups of women with an operable breast cancer. Ann Oncol 2005;16(11):1755–61.

Downloads

Published

2020-06-16

Most read articles by the same author(s)